IVIG in Patients With VGKC Ab Associated Autoimmune Epilepsy
A Randomized Double Blind Placebo Controlled Study of Intravenous Immunoglobulin (IVIG) Patients With Voltage Gated Potassium Channel Complex (VGKC) Antibody Associated Autoimmune Epilepsy
Sponsor: Grifols Shared Services North America
Terminated
This trial was terminated. No reason was provided.
A PHASE3 clinical study on Autoimmune Epilepsy, this trial is terminated or withdrawn. The trial is conducted by Grifols Shared Services North America and has accumulated 10 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE3
-
Jan 2021 — Dec 2022 [monthly]
Terminated PHASE3
▶ Show 5 earlier versions
-
Jan 2020 — Jan 2021 [monthly]
Terminated PHASE3
-
Jan 2019 — Jan 2020 [monthly]
Terminated PHASE3
Status: Recruiting → Terminated
-
Jun 2018 — Jan 2019 [monthly]
Recruiting PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Feb 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Grifols Shared Services North America
- Mayo Clinic
- Option Care
For direct contact, visit the study record on ClinicalTrials.gov .